SAHPRA SAPC Regulatory Enforcement: Addressing ...

By João L. Carapinha

May 26, 2026

SAHPRA SAPC regulatory enforcement has intensified following the seizure of all GLP-1 and GIP injectable products at iDexis (Pty) Ltd trading as Sentra Pharmacy. An inspection on 11 May 2026 revealed the facility was manufacturing and distributing...
Key Milestone in GBA-PD Therapy Development Achieved with ACTIVATE Study Comp...
Advancements in Perioperative Bladder Cancer Therapy: A Promising New Regimen
Hepcludex HDV Approval: A Breakthrough in Chronic Hepatitis Delta Treatment
CHMP Recommendations 2026: New Approvals and Implications for Health Economics
Novartis Oncology Advancements: Key Trial Findings and Market Implications
Baxfendy Hypertension Treatment: FDA Approves First-in-Class Aldosterone Synt...
Trastuzumab-Deruxtecan Reimbursement: A Careful Evaluation of Cost-Effectiven...
Portugal Health Spending 2025 Reaches Record €4.417 Billion Amid Rising Demand
PSA Response Improvement: Promising Data from Pluvicto in mHSPC Treatment
Financing Boosts Vaccine Manufacturing Africa: New Facility to Enhance Local ...
Enhertu Breast Cancer Treatment Gains FDA Approval in Neoadjuvant and Adjuvan...
Dynamic Risk Stratification in Thromboembolism Prevention for Cancer Patients